Use of Maxaquin in treatment and prophylaxis of urinary tract 2 infections (U T I)

1. Ronald A .R ., Tiirck М ., Petersdorf R.G . Acritical evaluation of nalidixic acid in urinary tract inferection / / N.Engl.J. M ed.— 1966.— Vol.275.— P. 1018— 1089.

2. Wolfson J.S ., Hooper D .С. Fluoroquinolone antimicrobial agents / / Clin.Microbiol. Rev.— 1989.— Vol.2.— P .378— 424.

3. Siporin C. The evolution of-fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicitics / / Annu. Rev. Microbiol.— 1989.— Vol.43.— P .601— 627.

4. Фармакокинетические свойства Максаквина / / Пульмонология.— 1993.— Приложение 1.

5. Структура и антибактериальная активность Максаквина / / Там же.

6. . Mouton J., Agana F., Chidiac C. et al. A multiccnter study of lomefloxacin and trimethoprim (sulfamehoxazole in the treatment of uncomplicated acute pyelonephritis / / Am. J. M ed.— 1992.— Vol.92, Suppl.4A.— P.87S— 90S.

7. Jravani A. Efficacy of lomefloxacin as compared to norfloxacin in the treatm ent of uncomplicated urinary tract infections in adults / / Ibib.— P.75S— 81S.

8. . Nabcr K.G. Lomefloxacin versus norfloxacin versus ciprofloxacin in the treatm ent of complicated urinary' tract infections / / Int. J. Antimicrob. Agents.— 1992.— V ol.2.— P .33— 38.

9. Cox C.E. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatm ent of complicated and recurrent urinary tract infections / / Am. J. Med.— 1992.— Vol.92, Suppl.4A.— P.82S— 86S.

10. Crom e P., Bruce-Jones P. Infection in the elderly: studies with lomefloxacin / / Ibib.— P.126S— 129S.

11. Обзор исследований по безопасности Максаквина / / Пульмонология.— 1993.— Приложение 1.

12. Klimberg I.W ., Childs S.J., Madore R.J., Klimberg S.R. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery / / Am. J. Med.— 1992.— Vol.92, Suppl.4A.— P .121S — 125S.

13. Charton М ., Mombet A ., Gattegno B. Urinary tract infection prophylaxis in transurethral surgery: oral lomefloxacin versus parenteral cefuroxime / / Ibid.— P.118S— 120S.

14. Piddock L.J.V., Hall M .C ., Wise R. Mechanism of action of lom efloxacin //Antimicrob . Agents Chemother.— 1990.— Vol.34.— P.1088— 1093.

15. Burnham J .C ., Sonstein S .A . Anti-virulence effect of lomefloxacine and other quinolones / / Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy .— Washington : American Society for Microbiology, 1990.— Abstract 1010.

16. Saharkhiz-Langroodi A ., Renk C.M. E ffect of subminimal inhibitory concentrations of lomefloxacin (NY-198, SC-47111) on phagocytosis of Staphylococcus aureus by human polymorphonuclear leukocytes / / Abstract of the 89th Annual Meeting of the American Society for Microbiology.— Washington: American Society for Microbiology, 1989.— P. 104.— Abstract D134.

17. Pruul. H , M cD onald P.J. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils / / J. Antimicrob. Chemother.— 1990.— Vol.25.— P .91 — 101.